Blocking the catalytic activity of proteasomes is a
tried-and-true strategy in multiple myeloma, but use of marketed inhibitors is
limited by drug resistance and lack of efficacy in solid tumors. Now, a team
from The Johns Hopkins University has
discovered a compound that suppresses tumor growth in vitro and in
animal models of multiple myeloma and ovarian cancer by blocking the regulatory
subunit of proteasomes.
lid on the mechanism
Boettner, B. SciBX 7(2);
Published online Jan. 16, 2014
1. Anchoori, R.K. et
al. Cancer Cell; published online Dec. 9, 2013;
Contact: Richard B.S. Roden, The Johns Hopkins University, Baltimore,
2. Goldberg, A.L. J.
Cell Biol. 199, 583-588 (2012)
3. Bazzaro, M. et al.
J. Med. Chem. 54, 449-456 (2011)
4. Förster, F. et al.
Structure 21, 1551-1562 (2013)
AND INSTITUTIONS MENTIONED
Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif.
California Institute of Technology, Pasadena, Calif.
Cytomics Pharmaceuticals, Orsay, France
Cleave Biosciences Inc., Burlingame, Calif.
Harvard Medical School, Boston, Mass.
Howard Hughes Medical Institute, Pasadena, Calif.
The Johns Hopkins University, Baltimore, Md.
Max Planck Institute of Biochemistry, Martinsried, Germany
Mayo Clinic, Scottsdale, Ariz.
Nereus Pharmaceuticals Inc., San Diego, Calif.
The Sidney Kimmel Comprehensive Cancer Center at The Johns
Hopkins University School of Medicine, Baltimore, Md.
Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan
Technical University Munich, Munich, Germany
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel